AU2005206570A1 - Tetrahydrocarboline compounds as anticancer agents - Google Patents

Tetrahydrocarboline compounds as anticancer agents Download PDF

Info

Publication number
AU2005206570A1
AU2005206570A1 AU2005206570A AU2005206570A AU2005206570A1 AU 2005206570 A1 AU2005206570 A1 AU 2005206570A1 AU 2005206570 A AU2005206570 A AU 2005206570A AU 2005206570 A AU2005206570 A AU 2005206570A AU 2005206570 A1 AU2005206570 A1 AU 2005206570A1
Authority
AU
Australia
Prior art keywords
substituted
beta
tetrahydro
carbolin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005206570A
Other languages
English (en)
Inventor
Paul Barsanti
Nathan Brammeier
Jie-Kai Cheng
David Dibble
Elisa Jazan
Zhi-Jie Ni
Sabina Pecchi
Megan Treutle
Weibo Wang
Kelly Wayman
Yi Xia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of AU2005206570A1 publication Critical patent/AU2005206570A1/en
Assigned to NOVARTIS VACCINES AND DIAGNOSTICS, INC. reassignment NOVARTIS VACCINES AND DIAGNOSTICS, INC. Request for Assignment Assignors: CHIRON CORPORATION
Assigned to NOVARTIS VACCINES AND DIAGNOSTICS, INC. reassignment NOVARTIS VACCINES AND DIAGNOSTICS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: CHIRON CORPORATION
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2005206570A 2004-01-23 2005-01-24 Tetrahydrocarboline compounds as anticancer agents Abandoned AU2005206570A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53898004P 2004-01-23 2004-01-23
US60/538,980 2004-01-23
PCT/US2005/002270 WO2005070930A2 (en) 2004-01-23 2005-01-24 Tetrahydrocarboline compounds as anticancer agents

Publications (1)

Publication Number Publication Date
AU2005206570A1 true AU2005206570A1 (en) 2005-08-04

Family

ID=34807249

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005206570A Abandoned AU2005206570A1 (en) 2004-01-23 2005-01-24 Tetrahydrocarboline compounds as anticancer agents

Country Status (9)

Country Link
US (1) US7855295B2 (cg-RX-API-DMAC7.html)
EP (1) EP1706404A2 (cg-RX-API-DMAC7.html)
JP (1) JP2007518822A (cg-RX-API-DMAC7.html)
CN (1) CN1910183A (cg-RX-API-DMAC7.html)
AU (1) AU2005206570A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0506977A (cg-RX-API-DMAC7.html)
CA (1) CA2554150A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06008211A (cg-RX-API-DMAC7.html)
WO (1) WO2005070930A2 (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004113300A1 (ja) 2003-06-23 2004-12-29 Ono Pharmaceutical Co., Ltd. 新規三環性複素環化合物
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US7601840B2 (en) 2004-03-15 2009-10-13 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
EP1829874B1 (en) 2004-12-22 2014-02-12 Ono Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
WO2008103470A2 (en) 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Oncogenic-ras-signal dependent lethal compounds
US11202775B2 (en) 2007-09-25 2021-12-21 Minerva Biotechnologies Corporation Methods for treatment of cancer
EP2214485B1 (en) * 2007-09-25 2016-07-20 Minerva Biotechnologies Corp. Methods for treatment of cancer
EP2050747A1 (en) * 2007-10-12 2009-04-22 BioAlliance Pharma Dimers of harmol or of its derivatives and uses thereof
CA2727055C (en) 2008-01-11 2016-12-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
CN101591348B (zh) * 2008-05-30 2011-07-27 首都医科大学 四氢咔啉酰氨基酸苄酯及其制备方法和应用
CN101597289B (zh) * 2008-06-02 2011-09-21 首都医科大学 2-色氨酰-β-四氢咔啉-3-甲酰基氨基酸苄酯及其制备方法和应用
WO2010138652A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating kaposi sarcoma
HUE052510T2 (hu) 2009-05-27 2021-05-28 Ptc Therapeutics Inc Módszerek a rák és a nem daganatos állapotok kezelésére
WO2010138644A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Processes for the preparation of substituted tetrahydro beta-carbolines
WO2010138685A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating prostate conditions
US8629158B2 (en) * 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003005A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
FR2953839A1 (fr) * 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
PL2592081T3 (pl) * 2010-07-06 2017-07-31 Ono Pharmaceutical Co., Ltd. Pochodna tetrahydrokarboliny
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US9353113B2 (en) 2011-03-18 2016-05-31 Ono Pharmaceutical Co., Ltd. Tetrahydrocarboline derivative
WO2013106414A1 (en) 2012-01-09 2013-07-18 X-Rx, Inc. Tryptoline derivatives having kinase inhibitory activity and uses thereof
CN103087062B (zh) * 2013-01-19 2015-06-03 安徽师范大学 N-磺酰基取代-β-四氢咔啉衍生物的制备方法
AP2015008858A0 (en) * 2013-05-28 2015-11-30 Astrazeneca Ab Chemical compounds
EP3352566A4 (en) * 2015-09-23 2019-07-31 Minerva Biotechnologies Corporation SCREENING METHOD FOR ACTIVE SUBSTANCES FOR DIFFERENTIATING STEM CELLS
JP2019001715A (ja) * 2015-10-30 2019-01-10 協和発酵キリン株式会社 三環性化合物
EP3378861B1 (en) * 2015-11-12 2021-08-04 Zhejiang Hisun Pharmaceutical Co., Ltd. Acrylic acid derivative, preparation method and use in medicine thereof
CN106967063B (zh) * 2017-03-21 2019-01-11 浙江大学 1-三氟甲基-1,2,3,4-四氢-β-咔啉衍生物及其制备方法
AU2018244449B2 (en) 2017-03-29 2024-07-11 Minerva Biotechnologies Corporation Agents for differentiating stem cells and treating cancer
US11458126B2 (en) 2017-08-01 2022-10-04 Ptc Therapeutics, Inc. DHODH inhibitor for use in treating hematologic cancers
WO2020072675A1 (en) 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)
CN110791389B (zh) * 2019-09-30 2021-06-01 义乌欧风汽车用品有限公司 一种除胶剂及其制备方法和应用
WO2023130070A2 (en) * 2021-12-31 2023-07-06 Ptc Therapeutics, Inc. Carboline compounds and use thereof
CN120265629A (zh) * 2022-11-07 2025-07-04 默克专利股份公司 被取代的双环和三环hset抑制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300541B1 (en) 1987-07-20 1996-03-27 Duphar International Research B.V 8,9-anellated-1,2,3,4-tetrahydro-beta-carboline derivatives
EP0357122A3 (en) * 1988-08-29 1991-10-23 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
JPH03287586A (ja) 1990-04-02 1991-12-18 Taisho Pharmaceut Co Ltd テトラヒドロ―β―カルボリン誘導体
JP3287586B2 (ja) 1991-07-09 2002-06-04 キヤノン株式会社 カラー画像処理方法、及びカラー画像処理装置
US5206377A (en) * 1991-12-05 1993-04-27 Whitby Research, Inc. Compounds useful as antiproliferative agents
US5622960A (en) * 1992-04-14 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Topoisomerase II inhibitors and therapeutic uses therefor
KR20000005175A (ko) 1996-04-04 2000-01-25 프리돌린 클라우스너, 롤란드 비. 보레르 테트라하이드로-베타-카르볼린 유도체의 항전이제로서의 용도
FR2796644B1 (fr) 1999-07-23 2001-09-07 Adir Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
US6720331B2 (en) * 2001-04-03 2004-04-13 National Sun Yat-Sen University 1-substituted 1,2,3,4-tetrahydro-β-carboline and 3,4-dihydro-β-carboline and analogs as antitumor agents
EP1438310B1 (en) * 2001-10-19 2006-12-20 TransTech Pharma Inc. Beta-carbolin derivatives as ptp-inhibitors

Also Published As

Publication number Publication date
US7855295B2 (en) 2010-12-21
JP2007518822A (ja) 2007-07-12
CA2554150A1 (en) 2005-08-04
MXPA06008211A (es) 2006-08-31
EP1706404A2 (en) 2006-10-04
WO2005070930A3 (en) 2006-01-19
CN1910183A (zh) 2007-02-07
US20050215580A1 (en) 2005-09-29
BRPI0506977A (pt) 2007-07-03
WO2005070930A2 (en) 2005-08-04

Similar Documents

Publication Publication Date Title
US7855295B2 (en) Tetrahydrocarboline compounds as anticancer agents
EP1689724B1 (en) Quinazolinone compounds as anticancer agents
EP1636225B1 (en) Pyridino 1,2-a pyrimidin-4-one compounds as anticancer agents
US7345046B2 (en) Heteroaryl-fused pyrimidinyl compounds as anticancer agents
JP2007500237A5 (cg-RX-API-DMAC7.html)
JP2007512368A5 (cg-RX-API-DMAC7.html)
KR100953246B1 (ko) 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
EP1732926B1 (en) Mitotic kinesin inhibitors
MXPA06011464A (en) Mitotic kinesin inhibitors
MXPA06005844A (en) Quinazolinone compounds as anticancer agents

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Free format text: FORMER APPLICANT(S): CHIRON CORPORATION

TH Corrigenda

Free format text: IN VOL 22, NO 24, PAGE(S) 2844 UNDER THE HEADING ASSIGNMENTS BEFORE GRANT, SECTION 113 - 2005 UNDERTHE NAME OF NOVARTIS VACCINES AND DIAGNOSTICS, INC. DELETE ALL REFERENCE TO 2005206570

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application